Italian CDMO Olon has announced the start of a construction on a €22 million facility for the production of ultra-potent compounds. These are aimed for use mainly as payloads and payload-linkers for antibody-drug conjugates (ADCs) at its site at Rodano, near Milan. The facility will reach containment OEB Level 6, with a target occupational exposure level (OEL) of 10 ng/m3.
Italian CDMO Olon is to invest €10 million to create an R&D hub at its headquarters site at Rodano near Milan. This will integrate seven existing R&D centres and will be dedicated entirely to research laboratories to be used to develop APIs and manufacturing processes.
Construction has started and is due to be completed in Q2 2023. This will also lead to about 50 new researchers being hired, bringing the corporate total to around 350.
Italian CDMO Olon has completed a large-scale high containment production line (OEL < 1 mg/m3) at its Rodano site at a cost of about €10 million. This is part of a planned €27 million it will roll out over 2022-3 that is fully allocated to the expansion of further internal expertise and capacity of high containment production. The new line, which is already operative, enables Olon to produce HPAPIs in batches of 30-250 kg.
During its 2020 results presentation, Italian API producer Olon announced the completion of a large-scale, multi-purpose, high-containment HPAPI production line at its Rodano site near Milan. This is already available to customers, the firm added.